A
If there’s a common theme in the errors of the US response to Covid-19, it’s been the astounding amount of squandering. Our leaders squandered time, as well as public trust and people’s economic and emotional resources. And they squandered the chance to do good science testing drugs and vaccines in a way that serves the public interest rather than the interest of pharmaceutical companies.
There’s no question that Covid-19 vaccines and therapies will save many lives. But we’re not doing the kinds of scientific studies needed to determine the best vaccines and therapies to maximize lives saved and minimize the weeks we endure unprecedented social and economic constraints. It’s not too late to change course.
The thing that s wrong with the COVID-19 vaccine trials We re not doing the kinds of scientific studies needed to get the most out of this work.
By Faye Flam, Bloomberg Opinion (TNS) December 22, 2020 11:22am Text size Copy shortlink:
If there s a common theme in the errors of the U.S. response to COVID-19, it s been the astounding amount of squandering. Our leaders squandered time, as well as public trust and people s economic and emotional resources. And they squandered the chance to do good science testing drugs and vaccines in a way that serves the public interest rather than the interest of pharmaceutical companies.
These updates are republished press releases and communications from members of the Science|Business Network
Amgen CEO: Greater U.S.-China collaboration will accelerate fight against cancer
Last month, Amgen CEO Bob Bradway helped kick off a high-level roundtable discussion focused on accelerating cancer research through greater collaboration between the U.S. and China. Held November 18 as part of the Bloomberg New Economy Forum, the Moonshot Roundtable discussion was co-facilitated by the Honorable Kevin Rudd, President of the Asia Society Policy Institute and former Prime Minister of Australia, and Dr. Bob Li, Physician Ambassador to China and Asia-Pacific at Memorial Sloan Kettering Cancer Center. The session brought together senior leaders from industry, academia and government.
What went wrong with the coronavirus vaccine trials newsday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newsday.com Daily Mail and Mail on Sunday newspapers.
Advanced Proteome Therapeutics Corp.: Advanced Proteome Therapeutics Announces Dr. Benjamin Krantz to Join Company as CEO
Advanced Proteome Therapeutics Corporation
(TSXV: APC) (FSE: 0E8)
( APC or the Company ), is pleased to announce that Dr. Benjamin Krantz will be joining the Company s US subsidiary Advanced Proteome Therapeutics Inc. ( APTI ) as CEO following the completion of his oncology fellowship at NYU Langone Health on July 1
st, 2021. Bill Dickie will continue his role as interim CEO of APTI until then and remain a member of the board of directors after.
Benjamin Krantz MD, MBA is the Chief Fellow in hematology/oncology at New York University Langone Medical Center and is currently on the Board of Directors at APTI. He completed his residency in internal medicine at New York-Presbyterian Hospital - Columbia University Medical Center during which time he analyzed investigator intellectual property disclosures as a Columbia Technology Ventures fellow. He subseque